Incyte's PD-1 priority review draws muted cheer — but analysts say it's all about getting a foot in the door
An eighth PD-(L)1 inhibitor is lining up at the FDA with the promise of bringing another big advance in cancer therapy. Just don’t expect it to be a blockbuster.
The latest entrant to the checkpoint inhibitor ring is Incyte, whose retifanlimab is slated for a decision by July 25 (likely just after GlaxoSmithKline’s dostarlimab) thanks to a priority review.
Following an example set by Regeneron and Sanofi with Libtayo, Incyte is shooting first for a niche indication — specifically, second-line late squamous cell carcinoma of the anal canal (SCAC). Lance Leopold, vice president of immuno-oncology clinical development, called it a “historically neglected, yet important, tumor.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.